GlassScriptPhysician profile
Kristene Smith
NPI 1003521238
$2,800.58
in general payments reported to CMS, 2019-2025
16 companies · $939 in 2025
The $939 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.64 · 2023: $1,033 · 2024: $814 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.39 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.26 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $276.25 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $183.92 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $129.85 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $126.64 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $114.12 | 2023 | Austedo Xr |
| Lundbeck LLC | $90.94 | 2024-2025 | Rexulti |
| Alkermes, INC. | $83.25 | 2023 | Aristada, Lybalvi |
| Tris Pharma INC | $55.17 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $50.97 | 2023-2025 | Trintellix |
| Biogen, INC. | $27.01 | 2023 | |
| Merck Sharp & Dohme LLC | $18.24 | 2023 | Belsomra |
| Owp Pharmaceuticals, INC. | $16.73 | 2025 | Subvenite |
| Collegium Pharmaceutical, INC. | $14.67 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $13.17 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristene Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.